Regen BioPharma Inc (RGBPP)
RGBPP is quoted over the counter, not listed on an exchange. Regen BioPharma Inc files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | RGBPP, quoted over the counter |
| SEC CIK | 0001589150 |
| OTC Markets tier | OTCID (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | La Mesa, CA |
| Incorporated in | NV |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements." | 10-Q 2026-08-17 |
| Cash and burn | $239 cash; operating cash flow -$111K a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,675,277,503 (2026-08-12); 31,554,704 a year earlier; 3,381,366 three years earlier. 3y figure adjusted for splits (2-for-1 overall). | Cover page 2026-08-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BCRG Group, Irvine, California, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-07-15 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2026-08-13 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-06-30 | $59K | -$638K | -$24K | $239 | $1.5M | $237K | 10-Q 2026-08-17 |
| Q2 2026 2026-03-31 | $59K | $992K | -$63K | $271 | $1.6M | $237K | 10-Q 2026-05-14 |
| Q1 2026 2025-12-31 | $59K | -$968K | -$198K | $5K | $1.9M | $237K | 10-Q 2026-02-13 |
| Q4 2025 2025-09-30 | $59K | -$572K | -$160K | $70K | $2.0M | $237K | 10-K 2025-12-30 |
| Q3 2025 2025-06-30 | $59K | -$167K | -$56K | $2K | $1.5M | $237K | 10-Q 2026-08-17 |
| Q2 2025 2025-03-31 | $59K | -$19K | -$101K | $2K | $968K | $237K | 10-Q 2026-05-14 |
| Q1 2025 2024-12-31 | $59K | -$515K | -$66K | $135 | $852K | $209K | 10-Q 2026-02-13 |
| Q4 2024 2024-09-30 | $59K | -$271K | -$207K | $716 | $1.3M | $182K | 10-K 2025-12-30 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 253G1 | 2025-12-05 |
| Latest annual report | 10-K | 2025-12-30 |
| Latest quarterly / interim | 10-Q | 2026-08-17 |
| Latest current report | 8-K | 2026-11-02 |
Source: SEC EDGAR submissions feed, 263 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier